专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2015099124A1 組換えフィブリノゲン高産生株及びその製造方法审中-公开
标题翻译：重组纤维素生产线及其生产方法
公开(公告)号：WO2015099124A1
公开(公告)日：2015-07-02
申请号：PCT/JP2014/084516
申请日：2014-12-26
申请人：一般社団法人日本血液製剤機構
发明人：宇野　修正 , 大瀧　桃子 , 村上　弘次 , 井手野　祥次
IPC分类号： C12N5/10 , C12N15/09 , C12P21/02
CPC分类号： C07K14/75 , C07K14/8121 , C07K14/8132 , C12N2510/02 , C12N2511/00
摘要：　本発明は、フィブリノゲン並びにα２ＰＩ及び／又はＰＡＩ－２を共発現する動物細胞株である、組換えフィブリノゲン高産生株、フィブリノゲンのＡα鎖、Ｂβ鎖及びγ鎖をコードする遺伝子、並びにα２ＰＩ及び／又はＰＡＩ－２をコードする遺伝子を動物細胞に導入し、該動物細胞中でフィブリノゲン並びにα２ＰＩ及び／又はＰＡＩ－２を共発現させることを含む、組換えフィブリノゲン高産生株の製造方法、並びに組換えフィブリノゲン高産生株を培地中で培養し、得られた培養物からフィブリノゲンを回収することを含む、組換えフィブリノゲンの製造方法を提供する。
摘要翻译：本发明提供：作为共表达纤维蛋白原和α2PI和/或PAI-2的动物细胞系的重组纤维蛋白原高产线; 一种生产重组纤维蛋白原高产线的方法，所述方法包括将编码Aα链，Bβ链和纤维蛋白原的γ链的基因和编码α2PI和/或PAI-2的基因导入动物细胞中，以及纤维蛋白原和α2PI和/或PAI-2在该动物细胞中的共表达; 以及重组纤维蛋白原的制造方法，该方法包括在培养基中培养重组纤维蛋白原高产线，从所得培养物中回收纤维蛋白原。

2. 发明申请

WO2003083104A1 METHOD FOR MAKING PURIFIED PLASMINOGEN ACTIVATOR-INHIBITOR TYPE 1 (PAI-1) AND PURIFIED PAI-1 MADE THEREFORM 审中-公开
标题翻译：制备纯化的PLASMINOGEN激活剂抑制剂1型（PAI-1）和纯化的PAI-1制剂的方法
公开(公告)号：WO2003083104A1
公开(公告)日：2003-10-09
申请号：PCT/US2003/005388
申请日：2003-02-20
申请人： MOLECULAR INNOVATIONS , DAY, Duane, D.
发明人： DAY, Duane, D.
IPC分类号： C12N9/99
CPC分类号： C07K19/00 , C07K14/8132 , Y10S514/836
摘要： The present disclosure relates to a single step method for purifying PAM, PAI-1 fragments and PAI-1 mutants using a metal chelate resin. The disclosure further relates to the purified PAM obtained by the disclosed method and uses for the purified PAI-1.
摘要翻译：本公开内容涉及使用金属螯合树脂纯化PAM，PAI-1片段和PAI-1突变体的单步方法。本公开还涉及通过所公开的方法获得的纯化的PAM并用于纯化的PAI-1。

3. 发明申请

WO1998007735A1 PANCREAS-DERIVED PLASMINOGEN ACTIVATOR INHIBITOR 审中-公开
标题翻译：胰蛋白酶衍生的PLASMINOGEN激活剂抑制剂
公开(公告)号：WO1998007735A1
公开(公告)日：1998-02-26
申请号：PCT/US1996013283
申请日：1996-08-16
申请人： HUMAN GENOME SCIENCES, INC. , NI, Jian , GENTZ, Reiner, L. , RUBEN, Steven, M.
发明人： HUMAN GENOME SCIENCES, INC.
IPC分类号： C07H21/04
CPC分类号： C07K14/8132 , A61K38/00 , Y02A50/463
摘要： The present invention relates to a novel member of the plasminogen activator inhibitor protein family. In particular, isolated nucleic acid molecules are provided encoding the pancreas-derived plasminogen activator inhibitor protein. Pancreas-derived plasminogen activator inhibitor polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to methods for treating physiologic and pathologic disease conditions and diagnostic methods for detecting pathologic disorders.
摘要翻译：本发明涉及纤溶酶原激活物抑制剂蛋白家族的新成员。特别地，提供编码胰腺衍生的纤溶酶原激活物抑制蛋白的分离的核酸分子。还提供了胰腺来源的纤溶酶原激活物抑制剂多肽，载体，宿主细胞和用于制备它们的重组方法。本发明还涉及用于治疗生理和病理疾病状况的方法以及用于检测病理学疾病的诊断方法。

4. 发明申请

WO9621416A3 METHODS AND COMPOSITIONS FOR TREATMENT OF SOLID TUMETHODS AND COMPOSITIONS FOR TREATMENT OF SOLID TUMORS IN VIVO MORS IN VIVO 审中-公开
标题翻译：治疗固体肿瘤的方法和组合物和用于治疗体内血液中固体肿瘤的组合物
公开(公告)号：WO9621416A3
公开(公告)日：1996-10-10
申请号：PCT/US9516855
申请日：1995-12-22
申请人： VIAGENE INC
发明人： BURROWS FRANCIS J , FONG TIMOTHY C , POLO JOHN M , DUBENSKY THOMAS W JR , JOLLY DOUGLAS J
IPC分类号： C12N15/09 , A61K35/76 , A61K38/00 , A61K38/45 , A61K45/00 , A61K48/00 , A61P35/00 , A61P43/00 , C07K14/57 , C07K14/705 , C07K14/745 , C07K14/81 , C12N5/10 , C12N9/02 , C12N9/12 , C12N9/64 , A61K
CPC分类号： C12N9/0069 , A61K38/00 , A61K48/00 , C07K14/57 , C07K14/705 , C07K14/745 , C07K14/8132 , C07K14/8146 , C12N9/1211 , C12N9/6491 , C12N2799/021 , C12N2799/027
摘要： The present invention provides compositions and methods for treatment of solid tumors with gene therapy utilizing recombinant viral vectors that express polypeptides which selectively initiate irreversible coagulation of blood in the tumor vasculature, inhibit tumor neovascularization, are capable of activating a non-toxic agent into a toxic agent within the tumor vascular wall causing destruction of the vascular bed and absorb or metabolize nutrients in the blood being supplied to the tumor. The production of these polypeptides by transduced cells in or adjacent to the blood vessels of the tumor result in the death of tumor cells.

5. 发明申请

WO1991003556A1 RECOMBINANT PRODUCT 审中-公开
标题翻译：重组产品
公开(公告)号：WO1991003556A1
公开(公告)日：1991-03-21
申请号：PCT/AU1990000396
申请日：1990-09-04
申请人： BIOTECHNOLOGY AUSTRALIA PTY LTD , WHITFELD, Peter, Lawrence , RICHARDSON, Michael, Andrew , BUNN, Clive, Leighton
发明人： BIOTECHNOLOGY AUSTRALIA PTY LTD
IPC分类号： C12N15/15
CPC分类号： C07K14/8132 , A61K38/00 , C07K2319/02 , C07K2319/036 , C07K2319/91 , C12N15/625
摘要： This invention relates to PAI-2 and its expression as a recombinant molecule in eukaryotic cell lines as a glycosylated secreted molecule, to the constructs expressing it, to host cells expressing it, to compositions comprising it, to methods of treatment, prophylaxis and diagnosis using it and to antibodies raised against it. The invention also provides a 414 amino acid form of PAI-2 wherein the N-terminal methionine residue is deleted, a 60 kD glycosylated secreted recombinant form of PAI-2 and compositions and methods using these molecules. The invention further relates to a novel synthetic signal peptide.
摘要翻译：本发明涉及PAI-2及其在作为糖基化分泌分子的真核细胞系中作为重组分子的表达，表达其的构建体，宿主表达细胞的组合物，包含其的组合物的方法，用于治疗，预防和诊断方法它和针对它的抗体。本发明还提供了414位氨基酸形式的PAI-2，其中N末端甲硫氨酸残基被缺失，60kD糖基化分泌的重组形式的PAI-2以及使用这些分子的组合物和方法。本发明还涉及一种新的合成信号肽。

6. 发明申请

WO1990010649A1 SERPIN RESISTANT CHYMOTRYPSIN SUPERFAMILY PROTEASES, PARTICULARLY PAI-1 RESISTANT +-PA, COMPLEMENTARY INHIBITOR MUTANTS; COMPOSITIONS; GENES; EXPRESSION 审中-公开
标题翻译： SERPIN抗性CHYMOTRYPSIN超级蛋白，特别是PAI-1抗性+ -PA，补充性抑制剂突变体; 组合物; 基因; 表达
公开(公告)号：WO1990010649A1
公开(公告)日：1990-09-20
申请号：PCT/US1990000947
申请日：1990-03-01
申请人： THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS ...
发明人： THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS ... , SAMBROOK, Joseph, F. , MADISON, Edwin, L. , GOLDSMITH, Elizabeth, J. , GETHING, Maryjane, H. , GERARD, Robert, D.
IPC分类号： C07K15/00
CPC分类号： C12N9/6459 , A61K38/00 , C07K14/8132 , C12N9/50 , C12N9/6427 , C12N15/102 , C12N15/71 , C12N15/85 , C12N2800/108 , C12N2830/00 , C12N2830/55 , C12Y304/21069
摘要： The present invention relates to serine protease mutants of the chymotrypsin superfamily, particularly +-PA mutants, that are resistant to inhibition by their cognate inhibitors, such as PAI-1 in the case of +-PA, and genes that encode the same. The present invention also relates to serine protease inhibitor mutants, particularly PAI-1 mutants, that inhibit the serine protease mutants of the present invention, particularly +-PA mutants, and genes that encode the same. The serine protease mutants and serine protease inhibitor mutants are useful as, e.g., pharmacological agents.
摘要翻译：本发明涉及对于其同源抑制剂如在+ -PA的情况下的PAI-1的抑制作用以及编码其的基因的糜蛋白酶超家族，特别是+ -PA突变体的丝氨酸蛋白酶突变体。本发明还涉及抑制本发明的丝氨酸蛋白酶突变体，特别是+ -PA突变体的丝氨酸蛋白酶抑制剂突变体，特别是PAI-1突变体，以及编码它们的基因。丝氨酸蛋白酶突变体和丝氨酸蛋白酶抑制剂突变体可用作例如药理学试剂。

7. 发明申请

WO1987006590A1 IMMUNOPOTENTIATION 审中-公开
标题翻译：免疫增强
公开(公告)号：WO1987006590A1
公开(公告)日：1987-11-05
申请号：PCT/AU1987000107
申请日：1987-04-16
申请人： BIOENTERPRISES PTY. LTD. , BARNES, Thomas, Michael , LEHRBACH, Philip, Ralph , RUSSELL-JONES, Gregory, John
发明人： BIOENTERPRISES PTY. LTD.
IPC分类号： C07K15/04
CPC分类号： C07K14/005 , A61K38/00 , A61K39/385 , A61K2039/523 , A61K2039/6068 , A61K2039/627 , C07K14/245 , C07K14/445 , C07K14/8132 , C07K2319/00 , C07K2319/035 , C07K2319/40 , C12N15/62 , C12N2720/12322
摘要： A class of carrier molecules which when linked to an immunogen can enhance the host's immune response to that immunogen regardless of whether the complex of carrier and immunogen is administered parenterally, enterally or orally to the host. The invention also provides processes for production of complexes according to the invention, as well as hybrid DNA sequences encoding complexes according to the invention, recombinant DNA molecules bearing said hybrid DNA sequences, transformant hosts and vaccines comprising complexes of the invention as well as methods for production of said vaccines.
摘要翻译：当与免疫原连接时，一类载体分子可以增强宿主对该免疫原的免疫应答，而不管载体和免疫原的复合物是否肠胃外，肠道或口服给予宿主。本发明还提供了用于制备根据本发明的复合物的方法，以及编码根据本发明的复合物的杂交DNA序列，携带所述杂交DNA序列的重组DNA分子，转化体宿主和包含本发明复合物的疫苗以及用于生产所述疫苗。

8. 发明申请

WO1986001212A1 MINACTIVIN 审中-公开
标题翻译：灭活素
公开(公告)号：WO1986001212A1
公开(公告)日：1986-02-27
申请号：PCT/AU1985000191
申请日：1985-08-13
申请人： BIOTECHNOLOGY AUSTRALIA PTY. LTD. , THE AUSTRALIAN NATIONAL UNIVERSITY , STEPHENS, Ross, Wentworth , GOLDER, Jeffrey, Philip , GOSS, Neil, Howard , ANTALIS, Toni, Marie
发明人： BIOTECHNOLOGY AUSTRALIA PTY. LTD. , THE AUSTRALIAN NATIONAL UNIVERSITY
IPC分类号： C07K15/06
CPC分类号： C07K14/8132 , A61K38/00 , G01N33/574 , G01N2333/811 , G01N2333/8132
摘要： Minactivin, a protein inactivator of urokinase-type plasminogen activator, has been shown to be a natural inactivator of this plasminogen activator which is associated with invasive tumours, and is therefore indicated as a crucial element in the body's normal defense against tumour invasion and metastasis. It may be produced by the cultivation of miniactivin-producing cells in vitro, and recovery of the cell culture supernatant. By controlling the culture conditions, the protein miniactivin may be produced in a partially purified form which may be used for diagnosis and treatment of tumours.
摘要翻译：尿激酶型纤溶酶原激活物的蛋白质灭活剂Minactivin已被证明是与侵袭性肿瘤相关的这种纤溶酶原激活物的天然灭活剂，因此被认为是身体对肿瘤浸润和转移的正常防御的关键因素。可以通过在体外培养细菌生成细胞并回收细胞培养上清来产生。通过控制培养条件，蛋白质微生物素可以部分纯化形式产生，其可用于诊断和治疗肿瘤。

9. 发明申请

WO2015026494A2 METHODS FOR TREATING TISSUE FIBROSIS 审中-公开
标题翻译：治疗组织纤维化的方法
公开(公告)号：WO2015026494A2
公开(公告)日：2015-02-26
申请号：PCT/US2014/048604
申请日：2014-07-29
申请人： TRUSTEES OF DARTMOUTH COLLEGE
发明人： MULLIGAN-KEHOE, Mary, Jo
IPC分类号： A61K38/55
CPC分类号： A61K38/57 , C07K14/8132
摘要： The present invention includes methods for reducing tissue damage in patients undergoing radiation treatment or with idiopathic pulmonary fibrosis or scleroderma by inhibiting PAI-1 activity in the tissue with a truncated PAI-1 agent, rPAI-1 23 .
摘要翻译：本发明包括通过用截短的PAI-1剂rPAI-123抑制组织中的PAI-1活性来减少经历放射治疗或特发性肺纤维化或硬皮病的患者的组织损伤的方法。

10. 发明申请

WO2009014564A3 MODIFIED PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 MOLECULE AND METHODS BASED THEREON 审中-公开
标题翻译：改良的PLASMINOGEN激活剂抑制剂类型1分子及其方法
公开(公告)号：WO2009014564A3
公开(公告)日：2010-03-11
申请号：PCT/US2008005272
申请日：2008-04-24
申请人： UNIV TOLEDO , JANKUN JERZY , SKRZYPCZAK-JANKUN EWA , SELMAN STEVEN H
发明人： JANKUN JERZY , SKRZYPCZAK-JANKUN EWA , SELMAN STEVEN H
IPC分类号： C12N15/00 , C12N15/09
CPC分类号： C07K14/8132 , A61K38/00
摘要： The present invention relates to a modified plasminogen activator inhibitor type- 1 (PAI-1) molecule that displays an increased in vivo half-life of the active form of PAI- 1, but is deficient in one or more functional activities as compared to the wild-type PAI- 1 protein. The modified PAI-1 molecule that displays an increased half-life further displays at least one of the following funtional characteristics: (i) decreased binding activity to at least one of the following molecules: urokinase plasminogen activator (uPA), tissue plasminogen activator (tPA) and vitronectin (Vn); and (ii) decreased specific activity against at least one of the following molecules: uPA, tPA and Vn. The invention further relates to pharmaceutical compositions comprising modified PAI-I molecules and methods of using these pharmaceutical compositions for treatment.
摘要翻译：本发明涉及改善的纤溶酶原激活物抑制剂1型（PAI-1）分子，其表现出活性形式的PAI-1的体内半衰期增加，但与一种或多种功能活性相比，缺乏一种或多种功能活性野生型PAI-1蛋白。显示增加的半衰期的修饰的PAI-1分子进一步显示以下功能特征中的至少一种：（i）降低与至少一种以下分子的结合活性：尿激酶纤溶酶原激活物（uPA），组织纤溶酶原激活剂 tPA）和玻连蛋白（Vn）; 和（ii）对下列分子中的至少一种分子的比活性降低：uPA，tPA和Vn。本发明还涉及包含改性PAI-1分子的药物组合物和使用这些药物组合物进行治疗的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式